HCA Healthcare
Stock Forecast, Prediction & Price Target
HCA Healthcare (HCA) stock Price Target by analysts
HCA Healthcare (HCA) stock Price Target by analysts
Average Price Target
$432.2
Potential upside: 7.51%
HCA Healthcare price prediction
What is HCA Healthcare stock analysts` prediction?
HCA Healthcare stock forecast: Based on 4 Wall Street analysts` predicted price targets for HCA Healthcare in the last 3 months, the avarage price target is $432.2, with a high forecast of $NaN. The average price target represents a 7.51% change from the last price of $402.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
HCA Healthcare stock Price Target by analysts
Full breakdown of analysts given HCA Healthcare price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Ann Hynes Mizuho Securities | 40% 2/5 | 11 months ago | $425 5.72% upside | $359.16 | StreetInsider | Previous targets (4) |
Michael Wiederhorn Oppenheimer | 25% 1/4 | 11 months ago | $400 -0.49% downside | $359.07 | StreetInsider | Previous targets (3) |
Matthew Gillmor KeyBanc | 0% 0/2 | 11 months ago | $420 4.47% upside | $359.07 | StreetInsider | Previous targets (1) |
Matthew Gillmor KeyBanc | 0% 0/2 | 11 months ago | $475 18.15% upside | $387.25 | TheFly | Previous targets (1) |
Pito Chickering Deutsche Bank | 25% 1/4 | 12 months ago | $441 9.70% upside | $406.01 | StreetInsider | Previous targets (3) |
David MacDonald Truist Financial | 0% 0/1 | about 1 year ago | $430 6.96% upside | $373.77 | TheFly | Previous targets (0) |
Pito Chickering Deutsche Bank | 25% 1/4 | about 1 year ago | $375 -6.71% downside | $335.04 | TheFly | Previous targets (3) |
Brian Tanquilut Jefferies | 50% 1/2 | over 1 year ago | $390 -2.98% downside | $336.82 | StreetInsider | Previous targets (1) |
Ben Hendrix RBC Capital | 50% 1/2 | over 1 year ago | $329 -18.15% downside | $311.07 | TheFly | Previous targets (1) |
Michael Wiederhorn Oppenheimer | 25% 1/4 | over 1 year ago | $345 -14.17% downside | $306.69 | TheFly | Previous targets (3) |
Pito Chickering Deutsche Bank | 25% 1/4 | over 1 year ago | $359 -10.69% downside | $327.25 | StreetInsider | Previous targets (3) |
Ben Hendrix RBC Capital | 50% 1/2 | over 2 years ago | $315 -21.64% downside | $285.91 | Benzinga | Previous targets (1) |
Ann Hynes Mizuho Securities | 40% 2/5 | over 2 years ago | $298 -25.87% downside | $285.91 | Benzinga | Previous targets (4) |
Michael Wiederhorn Oppenheimer | 25% 1/4 | over 2 years ago | $310 -22.88% downside | $285.91 | Benzinga | Previous targets (3) |
Unknown Goldman Sachs | N/A | over 2 years ago | $296 -26.36% downside | $257.09 | Benzinga | N/A |
Unknown UBS | N/A | over 2 years ago | $296 -26.36% downside | $257.85 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $243 -39.55% downside | $243.21 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $286 -28.85% downside | $239.7 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | almost 3 years ago | $265 -34.07% downside | $241.35 | Benzinga | N/A |
Unknown Raymond James | N/A | about 3 years ago | $250 -37.81% downside | $208.97 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $259 -35.57% downside | $210.25 | Benzinga | N/A |
Ann Hynes Mizuho Securities | 40% 2/5 | about 3 years ago | $230 -42.78% downside | $213.47 | Pulse 2.0 | Previous targets (4) |
Unknown Jefferies | N/A | about 3 years ago | $18 -95.52% downside | $217.16 | Benzinga | N/A |
Unknown Mizuho Securities | N/A | about 3 years ago | $230 -42.78% downside | $210.91 | Benzinga | N/A |
Unknown Wells Fargo | N/A | about 3 years ago | $199 -50.49% downside | $204.66 | Benzinga | N/A |
Unknown Stifel Nicolaus | N/A | about 3 years ago | $18 -95.52% downside | $203.94 | Benzinga | N/A |
Unknown Raymond James | N/A | about 3 years ago | $230 -42.78% downside | $198.63 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $240 -40.29% downside | $202.03 | Benzinga | N/A |
Unknown RBC Capital | N/A | about 3 years ago | $249 -38.05% downside | $198.53 | Benzinga | N/A |
Unknown Credit Suisse | N/A | about 3 years ago | $250 -37.81% downside | $202.87 | Benzinga | N/A |
Unknown Truist Financial | N/A | about 3 years ago | $240 -40.29% downside | $202.03 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $18 -95.52% downside | $181.31 | Benzinga | N/A |
Unknown Citigroup | N/A | about 3 years ago | $18 -95.52% downside | $181.31 | Benzinga | N/A |
Unknown Deutsche Bank | N/A | about 3 years ago | $18 -95.52% downside | $181.31 | Benzinga | N/A |
Unknown Barclays | N/A | about 3 years ago | $18 -95.52% downside | $181.31 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $212 -47.26% downside | $167.49 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | about 3 years ago | $233 -42.03% downside | $170.02 | Benzinga | N/A |
Unknown Deutsche Bank | N/A | about 3 years ago | $12 -97.01% downside | $169.39 | Benzinga | N/A |
Unknown Raymond James | N/A | about 3 years ago | $220 -45.27% downside | $172.6 | Benzinga | N/A |
Unknown Evercore ISI | N/A | about 3 years ago | $12 -97.01% downside | $172.6 | Benzinga | N/A |
Unknown Deutsche Bank | N/A | about 3 years ago | $200 -50.24% downside | $172.76 | Benzinga | N/A |
Unknown Mizuho Securities | N/A | about 3 years ago | $210 -47.76% downside | $168.06 | Benzinga | N/A |
Unknown RBC Capital | N/A | about 3 years ago | $256 -36.31% downside | $173.1 | Benzinga | N/A |
Joseph France Loop Capital Markets | 100% 1/1 | over 3 years ago | $240 -40.29% downside | $171.56 | TheFly | Previous targets (0) |
Unknown Stifel Nicolaus | N/A | over 3 years ago | $12 -97.01% downside | $211.79 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $9 -97.76% downside | $227.35 | Benzinga | N/A |
Unknown Mizuho Securities | N/A | over 3 years ago | $260 -35.32% downside | $215.7 | Benzinga | N/A |
Matt Borsch BMO Capital | 100% 1/1 | over 3 years ago | $240 -40.29% downside | $219.06 | Pulse 2.0 | Previous targets (0) |
Unknown UBS | N/A | over 3 years ago | $241 -40.04% downside | $210.9 | Benzinga | N/A |
Unknown Raymond James | N/A | over 3 years ago | $245 -39.05% downside | $210.5 | Benzinga | N/A |
HCA Healthcare Financial Estimates
HCA Healthcare Revenue Estimates
HCA Healthcare EBITDA Estimates
HCA Healthcare Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $58.75B N/A | $60.23B 2.52% | $64.96B 7.86% | Avg: $73.35B Low: $72.60B High: $74.01B avg. 12.91% | Avg: $77.28B Low: $76.39B High: $78.21B avg. 5.35% | Avg: $82.05B Low: $81.11B High: $83.04B avg. 6.17% | |
Net Income
% change YoY
| $6.95B N/A | $5.64B -18.87% | $5.24B -7.10% | Avg: $5.92B Low: $5.95B High: $6.98B avg. 13.08% | Avg: $6.34B Low: $6.37B High: $8.48B avg. 6.96% | Avg: $8.25B Low: $8.13B High: $8.38B avg. 30.20% | |
EBITDA
% change YoY
| $12.64B N/A | $12.06B -4.56% | $12.72B 5.41% | Avg: $14.64B Low: $14.49B High: $14.77B avg. 15.12% | Avg: $15.42B Low: $15.25B High: $15.61B avg. 5.35% | Avg: $16.38B Low: $16.19B High: $16.57B avg. 6.17% | |
EPS
% change YoY
| $21.51 N/A | $19.44 -9.62% | $19.24 -1.02% | Avg: $23.03 Low: $21.55 High: $25.27 avg. 19.70% | Avg: $26.11 Low: $23.05 High: $30.69 avg. 13.37% | Avg: $29.87 Low: $29.42 High: $30.33 avg. 14.38% | |
Operating Expenses
% change YoY
| $39.59B N/A | $41.80B 5.59% | $45.43B 8.68% | Avg: $33.61B Low: $33.27B High: $33.92B avg. -26.01% | Avg: $35.41B Low: $35.01B High: $35.84B avg. 5.35% | Avg: $37.60B Low: $37.17B High: $38.05B avg. 6.17% | |
FAQ
What is HCA Healthcare stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.74% in 2025-2027.
We have gathered data from 13 analysts. Their low estimate is 5.95B, average is 5.92B and high is 6.98B.
What is HCA Healthcare stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.14% in 2025-2027.
We have gathered data from 16 analysts. Their low revenue estimate is $72.60B, average is $73.35B and high is $74.01B.
What is HCA Healthcare stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.82% in 2025-2027.
We have gathered data from 13 analysts. Their low earnings per share estimate is $21.55, average is $23.03 and high is $25.27.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering HCA Healthcare stock. The most successful analyst is Ann Hynes whose win rate is 40%. He has correctly predicted 2/5 price targets.